Online inquiry

IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5387MR)

This product GTTS-WQ5387MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD2 gene. The antibody can be applied in Psoriasis, severe chronic plaque research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001328609.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 914
UniProt ID P06729
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5387MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9839MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ14154MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ8057MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ9610MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ8881MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ13114MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ10272MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LFG 316
GTTS-WQ9032MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMC RON-8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW